Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MP-2018
- Development stage
- Preclinical
- Lead developer
- Machavert Pharmaceuticals
- Modality
- Small Molecules
01
Overview
MP-2018 is a small molecule drug developed by Machavert Pharmaceuticals. It acts as an inhibitor of RAL GTPases, a class of small GTP-binding proteins involved in cell signaling pathways that regulate cell proliferation and survival. By inhibiting these targets, MP-2018 is being investigated for its potential antineoplastic (anticancer) effects, particularly in the treatment of non-small cell lung cancer and pancreatic cancer. As of June 2025, the drug remains in preclinical development with no reported clinical trial results or established dosing information[6].
- Other names
- RAL GTPase inhibitorsMachavert RAL inhibitors
02
Targets
Ral (Ral GTPases)
Beyond the preview
Go deeper on MP-2018.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MP-2018.